MedTrace Logo

Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)

NCT07023224 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2025-09-19

No results posted yet for this study

Summary

The aim of this methodological study was to investigate the Turkish validity and reliability of the Parkinson's Disease Dyskinesia Scale (PDYS-26).The scale evaluates choreic dyskinesia.Measures the impact of dyskinesia on activities of daily living in patients with Parkinson's disease.

Hypotheses of the Study:

* Parkinson's Disease Dyskinesia Scale (PDYS-26) is reliable in Turkish.
* Parkinson's Disease Dyskinesia Scale (PDYS-26) is valid in Turkish.

To determine the validity of dyskinesia;

* Tampa Kinesiophobia Scale,
* Mini BesTest,
* Activity Specific Balance Safety Scale (ABC) and
* Parkinson's Disease Questionnaire-39 will be evaluated.

Conditions

  • Idiopathic Parkinson Disease
  • Dyskinesias
  • Quality of Life

Interventions

OTHER

Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)

The Turkish adaptation of the Parkinson's Disease Dyskinesia Scale (PDYS-26) is administered to individuals diagnosed with Parkinson's disease who have a dyskinesia score of ≥1 based on the Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia item. The scale is used to evaluate dyskinesia severity and assess its clinical applicability in Turkish-speaking populations.

Sponsors & Collaborators

  • Izmir Bakircay University

    lead OTHER

Principal Investigators

  • Gulbın Ergın, PT, PhD · Izmir Bakircay Univercity

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-14
Primary Completion
2025-11-30
Completion
2025-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07023224 on ClinicalTrials.gov